Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.

BACKGROUND Codeletion of chromosome arms 1p and 19q (1p/19q codeletion) highly benefits diagnosis and prognosis in gliomas. In this study, we investigated the effect of 1p/19q codeletion on cancer cell metabolism and evaluated possible metabolic targets for tailored therapies. METHODS We combined in vivo 1H (proton) magnetic resonance spectroscopy (MRS) measurements in human gliomas with the analysis of a series of standard amino acids by liquid chromatography-mass spectroscopy (LC-MS) in human glioma biopsies. Sixty-five subjects with low-grade glioma were included in the study: 31 underwent the MRI/MRS examination, 47 brain tumor tissue samples were analyzed with LC-MS, and 33 samples were analyzed for gene expression with quantitative PCR. Additionally, we performed metabolic tracer experiments in cell models with 1p deletion. RESULTS We report the first in vivo detection of cystathionine by MRS in 1p/19q codeleted gliomas. Selective accumulation of cystathionine was observed in codeleted gliomas in vivo, in brain tissue samples, as well as in cells harboring heterozygous deletions for serine- and cystathionine-pathway genes located on 1p: phosphoglycerate dehydrogenase (PHGDH) and cystathionine gamma-lyase (CTH). Quantitative PCR analyses showed 40-50% lower expression of both PHGDH and CTH in 1p/19q codeleted gliomas compared with their non-codeleted counterparts. CONCLUSIONS Our results provide strong evidence of a selective vulnerability of codeleted gliomas to serine and glutathione depletion and point to cystathionine as a possible noninvasive marker of treatment response.

[1]  G. McBean.  The transsulfuration pathway: a source of cysteine for glutathione in astrocytes , 2011, Amino Acids.

[2]  E. Maher,et al.  Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[4]  R. Hegele,et al.  Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies. , 2009, Molecular genetics and metabolism.

[5]  M. Garwood,et al.  Simultaneous in vivo spectral editing and water suppression , 1998, NMR in biomedicine.

[6]  Ovidiu C. Andronesi,et al.  Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.

[7]  M. Sanson,et al.  Current therapeutic approaches to diffuse grade II and III gliomas , 2018, Therapeutic advances in neurological disorders.

[8]  S. Inoue,et al.  Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. , 2015, Cancer cell.

[9]  W. Vandertop,et al.  The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma , 2010, Acta Neuropathologica.

[10]  Stéphane Lehéricy,et al.  Brain dynamic neurochemical changes in dystonic patients: A magnetic resonance spectroscopy study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[11]  S. Niclou,et al.  Altered metabolic landscape in IDH‐mutant gliomas affects phospholipid, energy, and oxidative stress pathways , 2017, EMBO molecular medicine.

[12]  Karl J. Dykema,et al.  Somatic Pairing of Chromosome 19 in Renal Oncocytoma Is Associated with Deregulated ELGN2-Mediated Oxygen-Sensing Response , 2008, PLoS genetics.

[13]  Olivier Langlois,et al.  Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas , 2016, Nature Communications.

[14]  Christiane Portemer,et al.  Free amino acids and related substances in human glial tumours and in fetal brain: comparison with normal adult brain , 1976, Brain Research.

[15]  Omar S. Gómez,et al.  Cystathionine: A novel oncometabolite in human breast cancer. , 2016, Archives of Biochemistry and Biophysics.

[16]  F. Ducray,et al.  An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas , 2014, BioMed research international.

[17]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[18]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[19]  Christian M. Metallo,et al.  IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. , 2014, Cancer research.

[20]  Hai Yan,et al.  Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. , 2011, Current opinion in neurology.

[21]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[22]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. Vandertop,et al.  Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. , 2015, Cancer research.

[24]  Rolf Gruetter,et al.  Direct in vivo measurement of human cerebral GABA concentration using MEGA‐editing at 7 Tesla , 2002, Magnetic resonance in medicine.

[25]  M. Oshimura,et al.  Transplantation of Genetically Corrected Human iPSC-Derived Progenitors in Mice with Limb-Girdle Muscular Dystrophy , 2012, Science Translational Medicine.

[26]  A. Iafrate,et al.  Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate , 2018, Nature Communications.

[27]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[28]  G. Riggins,et al.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. , 2010, Cancer research.

[29]  Wolfgang Bogner,et al.  3D GABA imaging with real-time motion correction, shim update and reacquisition of adiabatic spiral MRSI , 2014, NeuroImage.

[30]  J. Barnholtz-Sloan,et al.  The epidemiology of glioma in adults: a "state of the science" review. , 2014, Neuro-oncology.

[31]  Olivier Delattre,et al.  Two types of chromosome 1p losses with opposite significance in gliomas , 2005, Annals of neurology.

[32]  O. Sansom,et al.  Modulating the therapeutic response of tumours to dietary serine and glycine starvation , 2017, Nature.

[33]  G. Georgiou,et al.  Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth , 2016, Nature Medicine.

[34]  Christian M. Metallo,et al.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.

[35]  G. Semenza,et al.  Decreased Expression of Cystathionine β-Synthase Promotes Glioma Tumorigenesis , 2014, Molecular Cancer Research.

[36]  G. Reifenberger,et al.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.

[37]  A. Iafrate,et al.  Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. , 2015, Cancer cell.

[38]  Stéphane Lehéricy,et al.  Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy , 2018, Neuro-oncology.

[39]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.